Combination Vaccine
AssigneeSeqirus Inc.
InventorsCheng Chang, Michael Cheung
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.
Claims82
An immunogenic composition comprising:
- a) a RNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operably linked to a regulatory element;
- and
- b) an antigen polypeptide selected from the group consisting of a RSV, an influenza virus and a SARS-CoV-2.
The immunogenic composition of 14, comprising, in order from 5′ to 3′:
- (i) the RNA comprising a nucleotide sequence encoding an antigen from a SARS-CoV-2;
- (ii) the RNA comprising a nucleotide sequence encoding an antigen from RSV.
The immunogenic composition of 14, comprising, in order from 5′ to 3′:
- (i) the RNA comprising a nucleotide sequence encoding an antigen from RSV;
- and
- (ii) the RNA comprising a nucleotide sequence encoding an antigen from a SARS-CoV-2.
The immunogenic composition of any one of claims wherein the nucleotide sequence encoding an antigen from a RSV has the sequence set forth in SEQ ID NO:1 or 3.
A method of treating or preventing or delaying progression of a disease or condition in a subject, the method comprising locally co-administering
- (i) a polynucleotide comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), influenza and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operably linked to a regulatory element;
- and
- (ii) an antigen polypeptide selected from the group consisting of a RSV, influenza and a SARS-CoV-2.
Dependencies are inferred from the claim text.